3- (4- chlorophenyl)- 3- (4- hydroxy- 3,5- dimethoxybenzyloxy)- 2- propyl- 2,3- dihydroisoindol- 1- one
structure in first source
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Ahmed, Shafiq U:
2 articles
(10/2006 - 03/2005)
|
2. | Atkins, Helen:
2 articles
(10/2006 - 03/2005)
|
3. | Farnie, Gillian:
2 articles
(10/2006 - 03/2005)
|
4. | Golding, Bernard T:
2 articles
(10/2006 - 03/2005)
|
5. | Griffin, Roger J:
2 articles
(10/2006 - 03/2005)
|
6. | Guyenne, Sabrina:
2 articles
(10/2006 - 03/2005)
|
7. | Hardcastle, Ian R:
2 articles
(10/2006 - 03/2005)
|
8. | Hutton, Claire:
2 articles
(10/2006 - 03/2005)
|
9. | Kemp, Stuart J:
2 articles
(10/2006 - 03/2005)
|
10. | Kitching, Martin S:
2 articles
(10/2006 - 03/2005)
|
Related Diseases
1. | Sarcoma (Soft Tissue Sarcoma)
10/19/2006
- " Two of the most potent compounds, 2-benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2,3-dihydroisoindol-1-one (76; IC(50) = 15.9 +/- 0.8 microM) and 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (79; IC(50) = 5.3 +/- 0.9 microM), induced p53-dependent gene transcription, in a dose-dependent manner, in the MDM2 amplified, SJSA human sarcoma cell line." 03/01/2005
- " The most potent compound, 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (NU8231), exhibited an IC50 of 5.3 +/- 0.9 microM in an ELISA assay, and induced p53-dependent gene transcription in a dose-dependent manner, in the SJSA human sarcoma cell line."
|
|
Related Drugs and Biologics